The stock of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) last traded at $36.00, up 6.13% from the previous session.
Data from the available sources indicates that PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is covered by 9 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $62.00 and a low of $39.00, we find $49.00. Given the previous closing price of $33.92, this indicates a potential upside of 44.46 percent. PRCT stock price is now 3.00% away from the 50-day moving average and -2.51% away from the 200-day moving average. The market capitalization of the company currently stands at $1.61B.
In total, 1 analysts have assigned it a hold rating, and 8 have given it a buy rating. Brokers who have rated the stock have averaged $50.14 as their price target over the next twelve months.
In other news, Nouri Alaleh, EVP, CLO, CORP. SEC. sold 7,903 shares of the company’s stock on Jul 27. The stock was sold for $316,129 at an average price of $40.00. Upon completion of the transaction, the EVP, CLO, CORP. SEC. now directly owns 46,933 shares in the company, valued at $1.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 15, EVP, CFO Waters Kevin sold 22,631 shares of the business’s stock. A total of $794,912 was realized by selling the stock at an average price of $35.12. This leaves the insider owning 33,523 shares of the company worth $1.21 million. Insiders disposed of 904,166 shares of company stock worth roughly $32.55 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PRCT stock. A new stake in PROCEPT BioRobotics Corporation shares was purchased by FRANK, RIMERMAN ADVISORS LLC during the first quarter worth $16,450,000. EXODUSPOINT CAPITAL MANAGEMENT, LP invested $12,202,000 in shares of PRCT during the first quarter. In the first quarter, EAGLE HEALTH INVESTMENTS LP acquired a new stake in PROCEPT BioRobotics Corporation valued at approximately $10,232,000. OSTERWEIS CAPITAL MANAGEMENT INC acquired a new stake in PRCT for approximately $3,061,000. TWO SIGMA INVESTMENTS, LP purchased a new stake in PRCT valued at around $2,979,000 in the second quarter.
With an opening price of $35.94 on Wednesday morning, PROCEPT BioRobotics Corporation (NASDAQ: PRCT) set off the trading day. During the past 12 months, PROCEPT BioRobotics Corporation has had a low of $25.29 and a high of $52.40. As of last week, the company has a debt-to-equity ratio of 0.30, a current ratio of 7.60, and a quick ratio of 6.40. The fifty day moving average price for PRCT is $35.03 and a two-hundred day moving average price translates $36.90 for the stock.
According to the Medical Devices Company, earnings per share came in at -$0.56, beating analysts’ expectations of -$0.57 by 0.01. This compares to -$0.43 EPS in the same period last year. The company reported revenue of $33.1 million for the quarter, compared to $16.69 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 98.33 percent. For the current quarter, analysts expect PRCT to generate $32.86M in revenue.
